Physician profile
Reginald Dickerson
NPI 1942290333
$3,389.46
in general payments reported to CMS, 2019-2025
22 companies · $83.27 in 2025
The $83.27 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2021: $198 · 2022: $524 · 2023: $1,622 · 2024: $773 · 2025: $83.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,247 · Travel and Lodging: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,247.35 |
| Travel and Lodging | $230.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $703.84 | 2023-2024 | Micra, Plasmablade(Tm) |
| Boston Scientific Corporation | $666.78 | 2019-2025 | Watchman Access System, Watchman Flx, Bodyguardian |
| Abbott Laboratories | $410.92 | 2021-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Perclose Prostyle |
| Amgen INC. | $331.13 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $283.87 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.13 | 2023-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $121.88 | 2021-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $104.93 | 2019-2024 | |
| Elutia, INC. | $65.25 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $62.38 | 2021-2024 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.95 | 2021-2024 | Lifevest |
| Pfizer INC. | $54.76 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $53.28 | 2024 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $45.60 | 2019-2024 | Eliquis |
| Scpharmaceuticals INC. | $40.47 | 2023-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Medical Corporation | $30.34 | 2024 | Defibrillator |
| Bayer Healthcare Pharmaceuticals INC. | $26.91 | 2024 | |
| Cvrx, INC. | $25.66 | 2024 | Barostim Neo System |
| Hologic Sales and Service, LLC | $24.01 | 2025 | Aptima |
| Novo Nordisk INC | $22.59 | 2024 | Rybelsus, Ozempic |
| Cardinal Health 200 LLC | $21.77 | 2019 | |
| Celonova Biosciences, INC. | $18.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reginald Dickerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.